Cadrenal Therapeutics Appoints Seasoned Interim CFO Amidst Going Concern, Director Resigns

summarizeSummary

Cadrenal Therapeutics appointed John P. Sharp, a highly experienced finance executive, as Interim CFO, replacing CEO Quang X. Pham in the interim role. A director also resigned, but not due to disagreements.

check_boxKey Events · Executive and Board Changes · CVKD

• Interim CFO Appointed

  John P. Sharp, a seasoned finance executive with over 30 years of experience, including multiple biopharmaceutical CFO roles, was appointed Interim Chief Financial Officer, effective June 25, 2026. He will provide services through Lohman & Associates, Inc. at $455/hour for up to 24 hours per week.

• Former Interim CFO Transition

  Quang X. Pham ceased to serve as the Company's Interim Chief Financial Officer, allowing him to focus on his role as Chairman and Chief Executive Officer.

• Director Resignation

  Steven Zelenkofske, a Class III Board member, resigned from the Board, effective June 30, 2026. The company stated his resignation was not due to any disagreement with operations, policies, or practices.

• Board Realignment

  Following the director resignation, Dr. Glynn Wilson resigned as a Class I director and was immediately reappointed as a Class III director, with updated committee assignments, to maintain board class balance.

auto_awesomeAnalysis · CVKD · Life Sciences

Cadrenal Therapeutics, a company operating under a reiterated going concern warning with a cash runway only into October 2026, has appointed John P. Sharp as Interim Chief Financial Officer. Mr. Sharp brings over 30 years of finance experience, including CFO roles at several biopharmaceutical companies. This move is significant as it brings experienced financial leadership to a company facing critical liquidity challenges, potentially strengthening its ability to manage its cash runway and secure future financing. Concurrently, Director Steven Zelenkofske resigned, though the company stated it was not due to any disagreement.